MaaT Pharma Reveals Promising Preclinical Data for MaaT034

MaaT Pharma has unveiled updated preclinical data for its drug candidate MaaT034 at the 40th Society for Immunotherapy Cancer Annual Meeting. The data underscores MaaT034's ability to enhance immune activation and show anti-tumor activity in germ-free mouse models. MaaT034, part of MaaT Pharma’s MET-C platform, aims to improve responses to immunotherapy in combination with Immune Checkpoint Inhibitors.

The findings reveal that MaaT034 successfully engrafts in the gut of mice, reproducing native microbiome functions. Moreover, its combination with anti-PD1 reduced tumor growth significantly. The data supports MaaT034's potential to optimize patient responses to immunotherapy. This development marks a pivotal advancement in MaaT Pharma's synthetic microbiome therapies, aiming to benefit cancer patients.